Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials.

Neil J Korman Richard Bruce Warren Jerry Bagel April W Armstrong Melinda J Gooderham Bruce E Strober Diamant Thaҫi Akimichi Morita Shinichi Imafuku Peter Foley Howard Sofen Min ZhengLauren HippeliRenata M KisaSubhashis BanerjeeAndrew Blauvelt

Published in: The Journal of dermatological treatment (2024)

Deucravacitinib displayed efficacy as early as 1 week and clinical responses were maintained over 52 weeks in patients with moderate to severe plaque psoriasis.

Keyphrases

coronary artery disease
atopic dermatitis
early onset
high intensity
gestational age
clinical trial
drug induced
study protocol
double blind